INmune Bio Stock Jumps On Promising Biomarker Data From Early-Stage Blood Cancer Trial

  • INmune Bio Inc INMB announced that the first patient who received INKmune has successfully shown NK activation and functional differentiation. INKmune is a potential candidate for high-risk myelodysplastic syndrome (MDS).
  • NK cells need multiple activating signals to progress from a resting state to the triggering of cytolysis and cytokine secretion. 
  • INmune Bio's study has demonstrated that the binding of NK cells with INKmune provides multiple activating signals and drives resting NK to the phenotype of memory-like NK (mlNK) cells with enhanced cancer-killing function. 
  • "In the lab, INKmune binds to multiple NK ligands and initiates the activation of over 3,000 genes associated with function, trafficking, proliferation, and survival to form memory-like NK cells, which have a superior cancer-killing function. 
  • Preliminary data from the first patient shows that the formation of mlNK cells can be achieved in vivo and without toxicity. Despite this high level of activated NK cells and tumor-killing, the patient showed no Cytokine Release Syndrome (CRS) symptoms.
  • At least nine additional patients with high-risk MDS will be enrolled in the ongoing Phase I trial.
  • Price Action: INMB stock is up 1.86% at $19.13 during the market session on the last check Thursday.

Posted In: Briefsmyelodysplastic syndromePhase 1 TrialBiotechLong IdeasNewsHealth CareSmall CapMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.